Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.

9 Oct 2025

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.

7 Oct 2025

Study finds surge in the use of weight loss drugs among bariatric surgery patients

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and Type 2 diabetes.

3 Oct 2025

Cannabidiol shows promise for obesity and metabolic syndrome

Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models of obesity and metabolic syndrome. However, human evidence is still limited, highlighting the need for rigorous trials before clinical use.

29 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase III clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

New genetic test can help predict how people will respond to weight-loss medications

Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Semaglutide

Overview

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest Semaglutide News and Research

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

Study finds surge in the use of weight loss drugs among bariatric surgery patients

Cannabidiol shows promise for obesity and metabolic syndrome

Orforglipron pill improves heart and metabolic risk factors in trial

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Scientists unveil new obesity drug that reprograms fat and energy use

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

New genetic test can help predict how people will respond to weight-loss medications

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

Higher-dose semaglutide helps people lose nearly 19% of body weight

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Individuals taking semaglutide for weight loss experience less food noise than before

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

Are GLP-1 drugs safe for women planning pregnancy?

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Semaglutide

Overview

Latest Semaglutide News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in